Delisting Determination,The Nasdaq Stock Market, LLC,
July 19, 2018, Rosetta Genomics Ltd. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the ordinary shares of Rosetta Genomics Ltd.
(the Company), effective at the opening of the trading
session on July 30, 2018. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5920(c)(1).
The Company was notified of the Staffs determination on
April 16, 2018.  The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
May 18, 2018, denying the Company continued listing
and notified the Company that trading in the Companys
securities would be suspended on May 22, 2018.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on July 2, 2018.